HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $146 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $146.
September 13, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences (NASDAQ:NBIX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $146.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Neurocrine Biosciences. The maintained price target of $146 indicates the firm's continued confidence in the company's potential, which could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100